ProCE Banner Activity

Randomized Phase II Study of Pevonedistat Plus Azacitidine vs Azacitidine: Post Hoc Analysis in Higher-Risk MDS

Slideset Download
Conference Coverage

Addition of pevonedistat to azacitidine significantly prolonged EFS, with a trend for extended OS and evidence of activity among patients with poor prognostic markers (eg, TP53).

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology